1. EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

3. Introduction

4. Introduction (cont)

5. PASI-75 and PASI-90 Responses

6. Treatment Goals: European Consensus

7. PASI-90 Is Associated With Improved DLQI Outcome

8. Proportion of Patients Achieving PASI-75 From Baseline to Week 12 (IXE)

9. Comparison of Ixekizumab With Etanercept or Placebo in Moderate-to-Severe Psoriasis (UNCOVER-2 and UNCOVER-3): Results From Two Phase 3 Randomized Trials

10. FIXTURE: Results on PASI for Secukinumab 300 mg

11. DLQI 0/1 Response at Week 12 and Week 52

12. Secukinumab Efficacy Data Over 2 Years Randomized Extension of ERASURE and FIXTURE

13. Secukinumab Efficacy Data Over Two Years Randomized Extension of ERASURE and FIXTURE

14. Secukinumab 300 mg Retreatment Response

15. Secukinumab vs Ustekinumab in Moderate-to-Severe Psoriasis Plaques CLEAR study Week 16 results

16. CASE VIGNETTE #1

17. Evolution Under Secukinumab

18. Secukinumab Rapidly Improved Plaque Psoriasis

19. PASI-75 Is Not Enough for Patients...

20. Evolution Under Secukinumab

21. Secukinumab, a First-Line Label in Moderate / Severe Psoriasis

22. Clinical Case

23. Clinical Case

24. Clinical Case

25. Clinical Case

26. Clinical Case

27. What the Patient Would Like to Expect From a Therapy

28. PASI-75 vs PASI-90

29. Secukinumab Benefit-Risk Ratio

30. A 43-Year-Old Man With a PASI-36

31. Other Findings

32. How do ACR Responses to Secukinumab Compare to the Therapeutic Environment?

33. Resolution of Dactylitis and Enthesitis in Response to Secukinumab

34. Conclusion

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)